There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), Genfit SA (GNFT – Research Report) and Biora Therapeutics (BIOR – Research Report) with bullish sentiments.
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune today and set a price target of $50.00. The company’s shares closed last Thursday at $14.96.
According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $29.57, a 98.2% upside from current levels. In a report issued on January 17, Evercore ISI also maintained a Buy rating on the stock with a $25.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Genfit SA (GNFT)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Genfit SA today and set a price target of $8.00. The company’s shares closed last Thursday at $4.25.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Genfit SA is a Moderate Buy with an average price target of $8.00.
Biora Therapeutics (BIOR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics, with a price target of $65.00. The company’s shares closed last Thursday at $4.17, close to its 52-week low of $1.95.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biora Therapeutics with a $65.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALT:
- Altimmune management to meet virtually with Piper Sandler
- Altimmune price target raised to $25 from $14 at Evercore ISI
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
- Altimmune Appoints Raymond Jordt as Chief Business Officer